Mallinckrodt (MNK) and ANI Pharmaceuticals Inc Common Stock (ANIP) Head-To-Head Analysis

Mallinckrodt (NYSE: MNK) and ANI Pharmaceuticals Inc Common Stock (NASDAQ:ANIP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, valuation, earnings and profitability.

Profitability

Get Mallinckrodt alerts:

This table compares Mallinckrodt and ANI Pharmaceuticals Inc Common Stock’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mallinckrodt	57.56%	11.59%	4.48%
ANI Pharmaceuticals Inc Common Stock	0.01%	27.16%	12.43%

Institutional and Insider Ownership

55.9% of ANI Pharmaceuticals Inc Common Stock shares are held by institutional investors. 1.8% of Mallinckrodt shares are held by insiders. Comparatively, 33.1% of ANI Pharmaceuticals Inc Common Stock shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Mallinckrodt has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, ANI Pharmaceuticals Inc Common Stock has a beta of 2.84, indicating that its share price is 184% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Mallinckrodt and ANI Pharmaceuticals Inc Common Stock, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mallinckrodt	1	13	5	0	2.21
ANI Pharmaceuticals Inc Common Stock	0	0	3	0	3.00

Mallinckrodt presently has a consensus price target of $30.16, indicating a potential upside of 58.23%. ANI Pharmaceuticals Inc Common Stock has a consensus price target of $82.33, indicating a potential upside of 21.26%. Given Mallinckrodt’s higher possible upside, analysts clearly believe Mallinckrodt is more favorable than ANI Pharmaceuticals Inc Common Stock.

Earnings & Valuation

This table compares Mallinckrodt and ANI Pharmaceuticals Inc Common Stock’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mallinckrodt	$3.22 billion	0.49	$2.13 billion	$7.49	2.54
ANI Pharmaceuticals Inc Common Stock	$176.84 million	4.53	-$1.07 million	$3.61	18.81

Mallinckrodt has higher revenue and earnings than ANI Pharmaceuticals Inc Common Stock. Mallinckrodt is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals Inc Common Stock, indicating that it is currently the more affordable of the two stocks.

Summary

ANI Pharmaceuticals Inc Common Stock beats Mallinckrodt on 8 of the 14 factors compared between the two stocks.

About Mallinckrodt

Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products. It offers H.P. Acthar Gel, an injectable drug for various indications, such as proteinuria, multiple sclerosis, infantile spasms, ophthalmic, neuromuscular disorders, dermatomyositis, polymyositis, rheumatology, and pulmonology; Inomax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Ofirmev, an intravenous formulation of acetaminophen for pain management; Therakos, an immunotherapy treatment platform; and Amitiza for the treatment of chronic idiopathic constipation. The company is also developing StrataGraft, which is in Phase III and II clinical development for the treatment of burns; terlipressin for the treatment of hepatorenal syndrome; MNK-1411 for the treatment of Duchenne muscular dystrophy; Stannsoporfin, a heme oxygenase inhibitor for the treatment of jaundice; Xenon gas for inhalation; MNK-6105, an ammonia scavenger for the treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia; VTS-270 that is in Phase III development for Niemann-Pick Type C, a neurodegenerative fatal disease; and CPP-1X/sulindac, which is in Phase III development for Familial Adenomatous Polyposis. Mallinckrodt public limited company markets its branded products to physicians, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. The company is based in Staines-Upon-Thames, the United Kingdom.

About ANI Pharmaceuticals Inc Common Stock

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis. It also provides Hydrocortisone Rectal Cream to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Lithium Carbonate ER and Lithobid for bipolar disorder; Mesalamine Enema to treat distal ulcerative colitis, proctosigmoiditis, or proctitis; Methazolamide to treat ocular conditions; and Metoclopramide and Reglan to treat gastroesophageal reflux. In addition, the company offers Nilutamide to treat metastatic prostate cancer; Nimodipine that reduces the ischemic deficits in patients with subarachnoid hemorrhage; Opium Tincture to treat diarrhea; Oxycodone capsules and oral solution for severe and chronic pain; Propafenone to treat arrhythmia; Propranolol ER, Inderal LA, and Pindolol for managing hypertension in patients with angina pectoris; and Vancomycin and Vancocin for use in treating C. difficile-associated diarrhea and enterocolitis. Further, it provides contract manufacturing services for other pharmaceutical companies. The company markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota.